IBRX ▼ -5.8% - ImmunityBio, Inc.
$IBRX ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
16-OCT-2026 11:49 AM ET
Share this post
More filings for $IBRX
IBRX ▼ -6.3% - ImmunityBio, Inc.Oct 16, 2026IBRX ▲ +2.1% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +2.1% - ImmunityBio, Inc.Oct 14, 2026IBRX ▲ +1.0% - ImmunityBio, Inc.Oct 14, 2026IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026IBRX ▼ -0.2% - ImmunityBio, Inc.Oct 14, 2026
View full $IBRX filing history →💬 Comments
Loading comments…
Leave a comment